<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="other"><front><journal-meta><journal-id journal-id-type="nlm-ta">J Obes</journal-id><journal-id journal-id-type="publisher-id">JOBES</journal-id><journal-title-group><journal-title>Journal of Obesity</journal-title></journal-title-group><issn pub-type="ppub">2090-0708</issn><issn pub-type="epub">2090-0716</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">21253513</article-id><article-id pub-id-type="pmc">3021887</article-id><article-id pub-id-type="doi">10.1155/2011/957268</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Study</subject></subj-group></article-categories><title-group><article-title>Perspectives of CB1 Antagonist in Treatment of Obesity: Experience of RIO-Asia</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Pan</surname><given-names>Changyu</given-names></name><xref ref-type="aff" rid="I1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Yoo</surname><given-names>Hyung Joon</given-names></name><xref ref-type="aff" rid="I2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ho</surname><given-names>Low-Tone</given-names></name><xref ref-type="aff" rid="I3"><sup>3, 4, 5</sup></xref><xref ref-type="aff" rid="I4"></xref><xref ref-type="aff" rid="I5"></xref><xref ref-type="corresp" rid="cor1">*</xref></contrib></contrib-group><aff id="I1"><sup>1</sup>Department of Endocrinology,  Chinese PLA,  General Hospital,  No. 28, Fuxing Road, Beijing 100853, China</aff><aff id="I2"><sup>2</sup>Division of Endocrinology and Metabolism,  Department of Internal Medicine,  Hangang Sacred Heart Hospital, 94-200,  Yeongdeungpo-Dong,  Yeongdeungpo-Gu Seoul 150-719, Republic of Korea</aff><aff id="I3"><sup>3</sup>Department of Medical Research &amp; Education,  Taipei Veterans General Hospital,  No. 201, Sec. 2,  Shih-Pai Road, Taipei 112, Taiwan</aff><aff id="I4"><sup>4</sup>Division of Endocrinology &amp; Metabolism,  Taipei Veterans General Hospital,  No. 201, Sec. 2,  Shih-Pai Road, Taipei 112, Taiwan</aff><aff id="I5"><sup>5</sup>Institute of Physiology,  National Yang-Ming University,  No. 155, Li-Nong Street,  Taipei 112, Taiwan</aff><author-notes><corresp id="cor1">*Low-Tone Ho: <email>ltho@vghtpe.gov.tw</email></corresp><fn fn-type="other"><p>Academic Editor: S. B. Heymsfield</p></fn></author-notes><pub-date pub-type="ppub"><year>2011</year></pub-date><pub-date pub-type="epub"><day>29</day><month>12</month><year>2010</year></pub-date><volume>2011</volume><elocation-id>957268</elocation-id><history><date date-type="received"><day>10</day><month>6</month><year>2010</year></date><date date-type="accepted"><day>9</day><month>11</month><year>2010</year></date></history><permissions><copyright-statement>Copyright © 2011 Changyu Pan et al.</copyright-statement><copyright-year>2011</copyright-year><license license-type="open-access"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p><offsets xml_i="3395" xml_f="3681" txt_i="11" txt_f="297">Rimonabant, a selective cannabinoid-1 (CB1) receptor antagonist, has been shown to reduce weight and enhance improvements in cardiometabolic risk parameters in Western populations. This study assessed these effects of rimonabant in Asian population. A total of 643 patients (BMI 25 kg/m</offsets><sup><offsets xml_i="3686" xml_f="3687" txt_i="297" txt_f="298">2</offsets></sup><offsets xml_i="3693" xml_f="3859" txt_i="298" txt_f="464"> or greater without diabetes) from China, Republic of Korea, and Taiwan were prescribed a hypocaloric diet (600 kcal/day deficit) and randomized to rimonabant 20 mg (</offsets><italic><offsets xml_i="3867" xml_f="3868" txt_i="464" txt_f="465">n</offsets></italic><offsets xml_i="3877" xml_f="3897" txt_i="465" txt_f="485"> = 318) or placebo (</offsets><italic><offsets xml_i="3905" xml_f="3906" txt_i="485" txt_f="486">n</offsets></italic><offsets xml_i="3915" xml_f="4143" txt_i="486" txt_f="714"> = 325) for 9months. The primary efficacy variable was weight change from baseline after 9 months of treatment.  Results showed that rimonabant group lost more weight than placebo, (LSM ± SEM of −4.7 ± 0.3 kg vs. −1.7 ± 0.3 kg, </offsets><italic><offsets xml_i="4151" xml_f="4152" txt_i="714" txt_f="715">P</offsets></italic><offsets xml_i="4161" xml_f="4293" txt_i="715" txt_f="844"> &lt; .0001). The 5% and 10% responders were 2 or 3 folds more in the rimonabant group (53.0% vs. 20.0% and 21.5% vs. 5.7%, resp.) (</offsets><italic><offsets xml_i="4301" xml_f="4302" txt_i="844" txt_f="845">P</offsets></italic><offsets xml_i="4311" xml_f="4472" txt_i="845" txt_f="1003"> &lt; .0001). Rimonabant also significantly increased HDL-cholesterol, decreased triglycerides and waist circumference,by 7.1%, 10.6%, and 2.8 cm, respectively (</offsets><italic><offsets xml_i="4480" xml_f="4481" txt_i="1003" txt_f="1004">P</offsets></italic><offsets xml_i="4490" xml_f="4859" txt_i="1004" txt_f="1370"> &lt; .0001). This study confirmed the comparable efficacy and safety profile of rimonabant in Asian population to Caucasians. Owing to the recent suspension of all the CB1 antagonists off the pharmaceutical market for weight reduction in Europe and USA, a perspective in drug discovery for intervening peripheral CB1 receptor in the management of obesity is discussed.</offsets></p></abstract></article-meta></front><body><sec sec-type="section" id="sec1"><title><offsets xml_i="4944" xml_f="4959" txt_i="1378" txt_f="1393">1. Introduction</offsets></title><p><offsets xml_i="4970" xml_f="5093" txt_i="1394" txt_f="1517">Overweight and obesity, a global phenomenon,  affects more than 1 billion adults, with 300 million being clinically obese [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="5124" xml_f="5125" txt_i="1517" txt_f="1518">1</offsets></xref><offsets xml_i="5132" xml_f="5396" txt_i="1518" txt_f="1782">]. With changing life styles and dietary patterns, obesity is rapidly increasing in epidemic proportions globally. In the national nutritional surveys of the 3 countries that participated in the RIO-Asia study, the obesity prevalence rates were at 14.7% in China [</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="5427" xml_f="5428" txt_i="1782" txt_f="1783">2</offsets></xref><offsets xml_i="5435" xml_f="5455" txt_i="1783" txt_f="1803">], 26.6% in Taiwan [</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="5486" xml_f="5487" txt_i="1803" txt_f="1804">3</offsets></xref><offsets xml_i="5494" xml_f="5517" txt_i="1804" txt_f="1827">], and 30.6% in Korea [</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="5548" xml_f="5549" txt_i="1827" txt_f="1828">4</offsets></xref><offsets xml_i="5556" xml_f="5582" txt_i="1828" txt_f="1854">] in the year 2001-2002.  </offsets></p><p><offsets xml_i="5589" xml_f="5682" txt_i="1855" txt_f="1948">Obesity is a complex metabolic disorder characterized by an imbalance in energy homeostasis [</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="5713" xml_f="5714" txt_i="1948" txt_f="1949">5</offsets></xref><offsets xml_i="5721" xml_f="5833" txt_i="1949" txt_f="2061">], abnormal development of adipose tissue, and deregulation of hormones and cytokines including adipocytokines [</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="5864" xml_f="5865" txt_i="2061" txt_f="2062">6</offsets></xref><offsets xml_i="5872" xml_f="5975" txt_i="2062" txt_f="2165">]. This chronic metabolic imbalance is associated with comorbidities such as cardiovascular disorders [</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="6006" xml_f="6007" txt_i="2165" txt_f="2166">7</offsets></xref><offsets xml_i="6014" xml_f="6031" txt_i="2166" txt_f="2183">], hypertension [</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="6062" xml_f="6063" txt_i="2183" txt_f="2184">8</offsets></xref><offsets xml_i="6070" xml_f="6086" txt_i="2184" txt_f="2200">], sleep apnea [</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="6117" xml_f="6118" txt_i="2200" txt_f="2201">9</offsets></xref><offsets xml_i="6125" xml_f="6147" txt_i="2201" txt_f="2223">], diabetes mellitus [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="6178" xml_f="6179" txt_i="2223" txt_f="2224">1</offsets></xref><offsets xml_i="6186" xml_f="6218" txt_i="2224" txt_f="2256">], and certain types of cancer [</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="6250" xml_f="6252" txt_i="2256" txt_f="2258">10</offsets></xref><offsets xml_i="6259" xml_f="6353" txt_i="2258" txt_f="2352">] and related morbidity/mortality. Besides weight loss and favorable cardiometabolic profile [</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="6385" xml_f="6387" txt_i="2352" txt_f="2354">11</offsets></xref><offsets xml_i="6394" xml_f="6536" txt_i="2354" txt_f="2496">], pharmacological interventions for obesity should address reduction in abdominal obesity and lower the risk of developing diabetes mellitus.</offsets></p><p><offsets xml_i="6543" xml_f="6856" txt_i="2497" txt_f="2810">G protein-coupled cannabinoid receptor, CB-1 of the endocannabinoid system (ECS), plays a crucial role in regulating feeding pattern, lipid metabolism, and energy homeostasis. CB-1 receptors are located in the central nervous system and peripheral tissues including adipocytes, pancreas, gut, liver, and muscle  [</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="6888" xml_f="6890" txt_i="2810" txt_f="2812">12</offsets></xref><offsets xml_i="6897" xml_f="7147" txt_i="2812" txt_f="3062">]. Rimonabant is a selective CB-1 antagonist drug to be developed for weight loss. Results of in vitro experiments have suggested the involvement of fourth and fifth transmembrane domains of the CB-1 receptor for high-affinity binding of rimonabant [</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="7179" xml_f="7181" txt_i="3062" txt_f="3064">13</offsets></xref><offsets xml_i="7188" xml_f="7190" txt_i="3064" txt_f="3066">, </offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="7222" xml_f="7224" txt_i="3066" txt_f="3068">14</offsets></xref><offsets xml_i="7231" xml_f="7424" txt_i="3068" txt_f="3261">]. Rimonabant has been shown to exert a peripheral effect on food intake by regulating Acrp30 (i.e.,  adiponectin) and insulin, hormones involved in lipid and glucose metabolism, respectively [</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="7455" xml_f="7456" txt_i="3261" txt_f="3262">5</offsets></xref><offsets xml_i="7463" xml_f="7617" txt_i="3262" txt_f="3416">]. The mechanism of the long-lasting weight loss through rimonabant may be associated with an increase in energy expenditure and/or metabolic activities [</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="7648" xml_f="7649" txt_i="3416" txt_f="3417">5</offsets></xref><offsets xml_i="7656" xml_f="7658" txt_i="3417" txt_f="3419">, </offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="7690" xml_f="7692" txt_i="3419" txt_f="3421">15</offsets></xref><offsets xml_i="7699" xml_f="7701" txt_i="3421" txt_f="3423">].</offsets></p><p><offsets xml_i="7708" xml_f="7724" txt_i="3424" txt_f="3440">Animal studies [</offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="7756" xml_f="7758" txt_i="3440" txt_f="3442">16</offsets></xref><offsets xml_i="7765" xml_f="7767" txt_i="3442" txt_f="3444">, </offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="7799" xml_f="7801" txt_i="3444" txt_f="3446">17</offsets></xref><offsets xml_i="7808" xml_f="7964" txt_i="3446" txt_f="3602">] and human trials have demonstrated the efficacy of rimonabant in inducing weight loss and improving dyslipidemia and insulin sensitivity. The RIO-Europe [</offsets><xref ref-type="bibr" rid="B18"><offsets xml_i="7996" xml_f="7998" txt_i="3602" txt_f="3604">18</offsets></xref><offsets xml_i="8005" xml_f="8030" txt_i="3604" txt_f="3629">] and RIO-North America [</offsets><xref ref-type="bibr" rid="B19"><offsets xml_i="8062" xml_f="8064" txt_i="3629" txt_f="3631">19</offsets></xref><offsets xml_i="8071" xml_f="8305" txt_i="3631" txt_f="3865">] clinical trials studied the weight loss in obese or overweight Caucasians treated with 20 mg rimonabant. At the end of a 1-year period, the weight loss was significantly greater in patients treated with rimonabant (−6.3 to −6.6 kg; </offsets><italic><offsets xml_i="8313" xml_f="8314" txt_i="3865" txt_f="3866">P</offsets></italic><offsets xml_i="8323" xml_f="8837" txt_i="3866" txt_f="4377"> &lt; .001 versus placebo, −1.6 to −1.8 kg). The proportion of patients who achieved 5% or greater decrease in body weight was 48.6–50.9% while a 10% or greater decrease was noted in 25.2–27.4% patients. A reduction in waist circumference (3.6 cm) and triglycerides (13.2%), as well as an increase in HDL-cholesterol (7.2%), was also observed in the rimonabant group. After 2 years of treatment with 20 mg rimonabant, the weight loss was maintained at 7.4 kg. Similar results were observed in the RIO-Lipid study [</offsets><xref ref-type="bibr" rid="B20"><offsets xml_i="8869" xml_f="8871" txt_i="4377" txt_f="4379">20</offsets></xref><offsets xml_i="8878" xml_f="9246" txt_i="4379" txt_f="4747">] which analyzed the efficacy of rimonabant 20 mg in overweight or obese Caucasians with dyslipidemia. A significant suggestion of the study was that in addition to weight reduction, rimonabant also mobilized abdominal fat and improved cardiovascular risk profile. Furthermore, although the adiponectin-elevating effect was indirect, it was independent of weight loss.</offsets></p><p><offsets xml_i="9253" xml_f="9414" txt_i="4748" txt_f="4909">The efficacy of rimonabant in Asian ethnicity has not yet been evaluated. Evidence shows that the incidence of obesity is increasing rapidly in Asian countries [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="9445" xml_f="9446" txt_i="4909" txt_f="4910">1</offsets></xref><offsets xml_i="9453" xml_f="9455" txt_i="4910" txt_f="4912">, </offsets><xref ref-type="bibr" rid="B21"><offsets xml_i="9487" xml_f="9489" txt_i="4912" txt_f="4914">21</offsets></xref><offsets xml_i="9496" xml_f="9498" txt_i="4914" txt_f="4916">, </offsets><xref ref-type="bibr" rid="B22"><offsets xml_i="9530" xml_f="9532" txt_i="4916" txt_f="4918">22</offsets></xref><offsets xml_i="9539" xml_f="9668" txt_i="4918" txt_f="5047">]. As stated above, Asian populations have a greater body fat content at a lower body mass index (BMI) compared with Caucasians [</offsets><xref ref-type="bibr" rid="B23"><offsets xml_i="9700" xml_f="9702" txt_i="5047" txt_f="5049">23</offsets></xref><offsets xml_i="9709" xml_f="9711" txt_i="5049" txt_f="5051">, </offsets><xref ref-type="bibr" rid="B24"><offsets xml_i="9743" xml_f="9745" txt_i="5051" txt_f="5053">24</offsets></xref><offsets xml_i="9752" xml_f="9930" txt_i="5053" txt_f="5231">]. Consequently, obesity-related metabolic disorders like dyslipidemia, hypertension, and type 2 diabetes are more frequently observed at lower BMI in Asians than in Caucasians [</offsets><xref ref-type="bibr" rid="B22"><offsets xml_i="9962" xml_f="9964" txt_i="5231" txt_f="5233">22</offsets></xref><offsets xml_i="9971" xml_f="10107" txt_i="5233" txt_f="5369">]. Hence, the WHO has redefined the classification of obesity based on BMI in Asians. The BMI cutoff was lowered in Asians to ≥23.0 kg/m</offsets><sup><offsets xml_i="10112" xml_f="10113" txt_i="5369" txt_f="5370">2</offsets></sup><offsets xml_i="10119" xml_f="10149" txt_i="5370" txt_f="5400"> for overweight and ≥25.0 kg/m</offsets><sup><offsets xml_i="10154" xml_f="10155" txt_i="5400" txt_f="5401">2</offsets></sup><offsets xml_i="10161" xml_f="10196" txt_i="5401" txt_f="5436"> for obesity compared to 25–30 kg/m</offsets><sup><offsets xml_i="10201" xml_f="10202" txt_i="5436" txt_f="5437">2</offsets></sup><offsets xml_i="10208" xml_f="10236" txt_i="5437" txt_f="5465"> for overweight and ≥30 kg/m</offsets><sup><offsets xml_i="10241" xml_f="10242" txt_i="5465" txt_f="5466">2</offsets></sup><offsets xml_i="10248" xml_f="10276" txt_i="5466" txt_f="5494"> for obesity in Caucasians [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="10307" xml_f="10308" txt_i="5494" txt_f="5495">1</offsets></xref><offsets xml_i="10315" xml_f="10317" txt_i="5495" txt_f="5497">, </offsets><xref ref-type="bibr" rid="B22"><offsets xml_i="10349" xml_f="10351" txt_i="5497" txt_f="5499">22</offsets></xref><offsets xml_i="10358" xml_f="10360" txt_i="5499" txt_f="5501">, </offsets><xref ref-type="bibr" rid="B25"><offsets xml_i="10392" xml_f="10394" txt_i="5501" txt_f="5503">25</offsets></xref><offsets xml_i="10401" xml_f="10404" txt_i="5503" txt_f="5506">]. </offsets></p><p><offsets xml_i="10411" xml_f="10604" txt_i="5507" txt_f="5700">The RIO-ASIA study evaluated the efficacy and safety of rimonabant 20 mg, along with a hypocaloric diet, in reducing weight and improving cardiometabolic risk factors in obese Asian population.</offsets></p></sec><sec sec-type="section" id="sec2"><title><offsets xml_i="10655" xml_f="10680" txt_i="5702" txt_f="5727">2. Methods and Procedures</offsets></title><sec sec-type="subsection" id="sec2.1"><title><offsets xml_i="10734" xml_f="10751" txt_i="5728" txt_f="5745">2.1. Study Design</offsets></title><p><offsets xml_i="10762" xml_f="10898" txt_i="5746" txt_f="5882">This phase 3, randomized, double-blind, placebo-controlled, parallel-group, multinational study was carried out in 32 centers in China (</offsets><italic><offsets xml_i="10906" xml_f="10907" txt_i="5882" txt_f="5883">n</offsets></italic><offsets xml_i="10916" xml_f="10944" txt_i="5883" txt_f="5911"> = 240), Republic of Korea (</offsets><italic><offsets xml_i="10952" xml_f="10953" txt_i="5911" txt_f="5912">n</offsets></italic><offsets xml_i="10962" xml_f="10983" txt_i="5912" txt_f="5933"> = 200), and Taiwan (</offsets><italic><offsets xml_i="10991" xml_f="10992" txt_i="5933" txt_f="5934">n</offsets></italic><offsets xml_i="11001" xml_f="11043" txt_i="5934" txt_f="5976"> = 203) between April 2006 and April 2007.</offsets></p><p><offsets xml_i="11050" xml_f="11177" txt_i="5977" txt_f="6104">After a screening period of 7 to 14 days, obese patients were randomized in a 1 : 1 ratio to treatment with rimonabant 20 mg  (</offsets><italic><offsets xml_i="11185" xml_f="11186" txt_i="6104" txt_f="6105">n</offsets></italic><offsets xml_i="11195" xml_f="11226" txt_i="6105" txt_f="6136"> = 318) once daily or placebo (</offsets><italic><offsets xml_i="11234" xml_f="11235" txt_i="6136" txt_f="6137">n</offsets></italic><offsets xml_i="11244" xml_f="11351" txt_i="6137" txt_f="6244"> = 325) for a 9-month period. Randomization was stratified based on BMI status at baseline as 25 to 27 kg/m</offsets><sup><offsets xml_i="11356" xml_f="11357" txt_i="6244" txt_f="6245">2</offsets></sup><offsets xml_i="11363" xml_f="11378" txt_i="6245" txt_f="6257"> or &gt;27 kg/m</offsets><sup><offsets xml_i="11383" xml_f="11384" txt_i="6257" txt_f="6258">2</offsets></sup><offsets xml_i="11390" xml_f="12084" txt_i="6258" txt_f="6952">. Follow-up visits were scheduled every 28 days throughout the study duration. Study participants were prescribed at baseline a hypocaloric diet for the study duration. The calorie requirement was calculated based on basal metabolism rate and physical activity, from which 600 kcal/day was subtracted to calculate the recommended diet. A food intake assessment was carried out on day 84, day 168, and day 252 from diet diary entries. The protocol, approved by the Institutional Review Boards/Ethics Committees for each centre, was conducted in compliance with the Helsinki Declaration and with an independent, unblinded data monitoring committee. All patients provided written informed consent.</offsets></p></sec><sec sec-type="subsection" id="sec2.2"><title><offsets xml_i="12140" xml_f="12153" txt_i="6954" txt_f="6967">2.2. Patients</offsets></title><p><offsets xml_i="12164" xml_f="12606" txt_i="6968" txt_f="7404">Eligible patients were aged ≥18 years with a BMI ≥25 kg/m². Exclusion criteria were a body weight fluctuation of at least 5 kg in the previous 3 months, a systolic blood pressure &gt;165 mm Hg and/or diastolic blood pressure &gt;105 mm Hg at screening and baseline, presence of type 1  or type 2 diabetes, presence of any clinically significant disorders (endocrine/metabolic/neurological/psychological disorders; presence/history of cancer).</offsets></p></sec><sec sec-type="subsection" id="sec2.3"><title><offsets xml_i="12662" xml_f="12691" txt_i="7406" txt_f="7435">2.3. Measures and Assessments</offsets></title><p><offsets xml_i="12702" xml_f="13034" txt_i="7436" txt_f="7768">The primary efficacy endpoint was the absolute weight change from baseline (randomization) to 9 months in the intent-to-treat (ITT) population. Secondary efficacy endpoints were waist circumference (as a marker of change in abdominal obesity), high-density lipoprotein (HDL)-cholesterol, triglycerides, fasting insulin, and glucose.</offsets></p><p><offsets xml_i="13041" xml_f="13155" txt_i="7769" txt_f="7883">Measurement of body weight was carried out at each visit using a calibrated scale. Based on established protocol [</offsets><xref ref-type="bibr" rid="B26"><offsets xml_i="13187" xml_f="13189" txt_i="7883" txt_f="7885">26</offsets></xref><offsets xml_i="13196" xml_f="13876" txt_i="7885" txt_f="8565">], 3 waist measurements were taken in centimeters at the midpoint between the lower rib margin and the iliac crest. The variations in these measurements were expected to be ≤1.0 cm. Failure to fit within these criteria would lead to a fourth measurement. Metabolic parameters, including glucose, insulin, glycosylated hemoglobin (HbA1c), total cholesterol, low-density lipoprotein (LDL)-cholesterol, HDL-cholesterol, and triglycerides, were measured under fasting conditions on day 84, day 168, and day 252 in a central laboratory. Safety assessments consisted of spontaneously reported adverse events, clinical examinations, laboratory tests, vital signs, and electrocardiograms.</offsets></p></sec><sec sec-type="subsection" id="sec2.4"><title><offsets xml_i="13932" xml_f="13957" txt_i="8567" txt_f="8592">2.4. Statistical Analysis</offsets></title><p><offsets xml_i="13968" xml_f="14808" txt_i="8593" txt_f="9433">The sample size calculations for the study were derived from the RIO-Europe study and were based on a test to compare the mean change in weight (primary variable) and HDL-cholesterol (secondary confirmatory variable) from baseline between the 2 groups. The calculations of sample sizes were done using the sample size software nQuery Advisor 4.0. Thus with a standard deviation (SD) of 6.5 kg, 200 randomized patients (100 patients/group) were required to detect a mean treatment difference of 3 kg in weight. For HDL-cholesterol change, with a common SD of 25%, 414 randomized patients (207 patients/group) were required to detect a mean treatment difference of 8% in HDL-cholesterol. Finally, to fulfill the country/region requirements for the number of exposed patients, a total of 640 patients had to be randomized (320 patients/group).</offsets></p><p><offsets xml_i="14815" xml_f="15096" txt_i="9434" txt_f="9715">Statistical analysis was performed using SAS version 8.2 or higher. All statistical tests were 2-sided at the 5% significance level. Efficacy analyses were performed in ITT population, which consisted of all randomized patients and was the primary population for efficacy analyses.</offsets></p><p><offsets xml_i="15103" xml_f="15409" txt_i="9716" txt_f="10022">The absolute change in body weight from baseline to 9 months was analyzed using a 3-way analysis of covariance (ANCOVA) model, which included 3 fixed effects—treatment, country/region, and randomization stratum—and 1 covariate, baseline weight. Rimonabant 20 mg was compared with placebo using a Student's </offsets><italic><offsets xml_i="15417" xml_f="15418" txt_i="10022" txt_f="10023">t</offsets></italic><offsets xml_i="15427" xml_f="15606" txt_i="10023" txt_f="10202">-test within the framework of the ANCOVA model. In addition, a 95% confidence interval (CI) was constructed for the difference in mean absolute weight changes between the groups. </offsets></p><p><offsets xml_i="15613" xml_f="15980" txt_i="10203" txt_f="10570">Patients who achieved a 5% or 10% reduction in body weight from baseline at 9 months were classified as 5% or 10% responders. The proportion of 5% or 10% responders in the rimonabant 20-mg group was compared with placebo using a logistic regression model with 3 fixed effects—treatment, country/region, and randomization stratum—and 1 covariate, baseline body weight.</offsets></p><p><offsets xml_i="15987" xml_f="16390" txt_i="10571" txt_f="10974">Secondary efficacy endpoints were analyzed at 9 months using the ITT population. With the exception of the lipid parameters, continuous secondary efficacy endpoints were assessed as the absolute change from baseline at 9 months. Lipid parameters, except total cholesterol/HDL-cholesterol ratio, were assessed as relative change from baseline and analyzed as described for the other secondary end points.</offsets></p><p><offsets xml_i="16397" xml_f="16686" txt_i="10975" txt_f="11264">In the efficacy analyses of endpoints for the ITT population, the last observation carried forward method (LOCF) was used to account for missing assessments or patients who prematurely discontinued. These endpoints were replaced by the last available postbaseline on-treatment observation.</offsets></p></sec></sec><sec sec-type="section" id="sec3"><title><offsets xml_i="16743" xml_f="16753" txt_i="11267" txt_f="11277">3. Results</offsets></title><sec sec-type="subsection" id="sec3.1"><title><offsets xml_i="16807" xml_f="16820" txt_i="11278" txt_f="11291">3.1. Patients</offsets></title><p><offsets xml_i="16831" xml_f="16966" txt_i="11292" txt_f="11427">A total of 643 patients   were randomized  (318 in the rimonabant 20 mg group  and 325 in the placebo group) from 32 centers in China (</offsets><italic><offsets xml_i="16974" xml_f="16975" txt_i="11427" txt_f="11428">n</offsets></italic><offsets xml_i="16984" xml_f="17012" txt_i="11428" txt_f="11456"> = 240), Republic of Korea (</offsets><italic><offsets xml_i="17020" xml_f="17021" txt_i="11456" txt_f="11457">n</offsets></italic><offsets xml_i="17030" xml_f="17051" txt_i="11457" txt_f="11478"> = 200), and Taiwan (</offsets><italic><offsets xml_i="17059" xml_f="17060" txt_i="11478" txt_f="11479">n</offsets></italic><offsets xml_i="17069" xml_f="17220" txt_i="11479" txt_f="11630"> = 203)—1 patient randomized to the placebo group did  not receive the study treatment. A higher percentage of patients in the rimonabant 20 mg group (</offsets><italic><offsets xml_i="17228" xml_f="17229" txt_i="11630" txt_f="11631">n</offsets></italic><offsets xml_i="17238" xml_f="17323" txt_i="11631" txt_f="11716"> = 285, 89.6%) completed the study treatment period compared with the placebo group (</offsets><italic><offsets xml_i="17331" xml_f="17332" txt_i="11716" txt_f="11717">n</offsets></italic><offsets xml_i="17341" xml_f="17357" txt_i="11717" txt_f="11733"> = 265, 81.5%) (</offsets><xref ref-type="fig" rid="fig1"><offsets xml_i="17389" xml_f="17397" txt_i="11733" txt_f="11741">Figure 1</offsets></xref><offsets xml_i="17404" xml_f="17842" txt_i="11741" txt_f="12179">). 11 patients were excluded from the ITT population (1 for nonexposure and 10 for missing postbaseline weight assessment); thus, the ITT population consisted of 632 patients (317 and 315 patients on placebo and rimonabant 20 mg groups, resp.). Treatment compliance was similar in both treatment groups: 98.7% and 96.9%; patients in the rimonabant and placebo groups, respectively, achieved 80% treatment compliance target (data on file).</offsets></p><p><offsets xml_i="17849" xml_f="18015" txt_i="12180" txt_f="12346">Demographic and baseline characteristics were similar between the 2 treatment groups, with equal distribution of patients across treatment in the 3 countries (Tables </offsets><xref ref-type="table" rid="tab1"><offsets xml_i="18049" xml_f="18050" txt_i="12346" txt_f="12347">1</offsets></xref><offsets xml_i="18057" xml_f="18062" txt_i="12347" txt_f="12352"> and </offsets><xref ref-type="table" rid="tab2"><offsets xml_i="18096" xml_f="18097" txt_i="12352" txt_f="12353">2</offsets></xref><offsets xml_i="18104" xml_f="18429" txt_i="12353" txt_f="12675">). 14.5% patients had hypertension, and 22.7% were dyslipidemic. Mean age was 36 ± 10.7 years with more than two thirds of patients being women (68.5%). Mean BMI was 30.26 ± 4.23 kg/m² with a baseline weight ranged from 54.3 to 161.5 kg and a mean weight of 81.48 ± 15.67 kg. Majority of patients (78.0%) had BMI &gt; 27 kg/m</offsets><sup><offsets xml_i="18434" xml_f="18435" txt_i="12675" txt_f="12676">2</offsets></sup><offsets xml_i="18441" xml_f="18609" txt_i="12676" txt_f="12844">. More than one third of patients had low HDL-cholesterol (34.1%), high triglycerides (31.3%), and high LDL-cholesterol (32.7%), and 17.4% had impaired fasting glucose.</offsets></p></sec><sec sec-type="subsection" id="sec3.2"><title><offsets xml_i="18665" xml_f="18676" txt_i="12846" txt_f="12857">3.2. Weight</offsets></title><p><offsets xml_i="18687" xml_f="18951" txt_i="12858" txt_f="13122">In the ITT population, weight loss was significantly greater in the rimonabant group (least square (LS) mean ± SEM: −4.7 ± 0.3) than in the placebo group (LS mean ± SEM: −1.7 ± 0.3) at 9 months, leading to a placebo-subtracted weight loss of approximately 3.0 kg (</offsets><italic><offsets xml_i="18959" xml_f="18960" txt_i="13122" txt_f="13123">P</offsets></italic><offsets xml_i="18969" xml_f="18983" txt_i="13123" txt_f="13134"> &lt; .0001) (</offsets><xref ref-type="fig" rid="fig2"><offsets xml_i="19015" xml_f="19026" txt_i="13134" txt_f="13145">Figure 2(a)</offsets></xref><offsets xml_i="19033" xml_f="19169" txt_i="13145" txt_f="13281">). When expressed as a percentage, rimonabant-treated patients lost 6.0% of their baseline body weight versus 2.3% in the placebo group.</offsets></p><p><offsets xml_i="19176" xml_f="19454" txt_i="13282" txt_f="13560">The percentage of patients who achieved at least a 5% reduction and 10% reduction from their baseline body weight at 9 months  in the rimonabant 20-mg group (53.0% and 20.0%, resp.) was more than 2-fold and 3-fold higher compared with the placebo group (21.5% and 5.7%, resp.) (</offsets><italic><offsets xml_i="19462" xml_f="19463" txt_i="13560" txt_f="13561">P</offsets></italic><offsets xml_i="19472" xml_f="19508" txt_i="13561" txt_f="13594"> &lt; .0001) in the ITT population (</offsets><xref ref-type="fig" rid="fig2"><offsets xml_i="19540" xml_f="19551" txt_i="13594" txt_f="13605">Figure 2(b)</offsets></xref><offsets xml_i="19558" xml_f="19561" txt_i="13605" txt_f="13608">). </offsets></p><p><offsets xml_i="19568" xml_f="19621" txt_i="13609" txt_f="13662">Treatment with rimonabant resulted in a significant (</offsets><italic><offsets xml_i="19629" xml_f="19630" txt_i="13662" txt_f="13663">P</offsets></italic><offsets xml_i="19639" xml_f="19727" txt_i="13663" txt_f="13748"> &lt; .001) decrease in weight in both BMI strata. In patients with BMI of 25 to 27 kg/m</offsets><sup><offsets xml_i="19732" xml_f="19733" txt_i="13748" txt_f="13749">2</offsets></sup><offsets xml_i="19739" xml_f="19755" txt_i="13749" txt_f="13762"> and &gt;27 kg/m</offsets><sup><offsets xml_i="19760" xml_f="19761" txt_i="13762" txt_f="13763">2</offsets></sup><offsets xml_i="19767" xml_f="19935" txt_i="13763" txt_f="13931">, the percentage of weight decrease was 5.61% and 6.11%, respectively, with rimonabant 20 mg while the corresponding changes in the placebo group were 2.05% and 2.31% (</offsets><xref ref-type="table" rid="tab3"><offsets xml_i="19969" xml_f="19976" txt_i="13931" txt_f="13938">Table 3</offsets></xref><offsets xml_i="19983" xml_f="19988" txt_i="13938" txt_f="13943"> and </offsets><xref ref-type="fig" rid="fig3"><offsets xml_i="20020" xml_f="20028" txt_i="13943" txt_f="13951">Figure 3</offsets></xref><offsets xml_i="20035" xml_f="20037" txt_i="13951" txt_f="13953">).</offsets></p></sec><sec sec-type="subsection" id="sec3.3"><title><offsets xml_i="20093" xml_f="20137" txt_i="13955" txt_f="13999">3.3. Changes in Secondary Efficacy Variables</offsets></title><p><offsets xml_i="20148" xml_f="20255" txt_i="14000" txt_f="14107">At 9 months, the percentage change in HDL-cholesterol revealed a steady increase in both treatment groups (</offsets><xref ref-type="fig" rid="fig4"><offsets xml_i="20287" xml_f="20298" txt_i="14107" txt_f="14118">Figure 4(a)</offsets></xref><offsets xml_i="20305" xml_f="20376" txt_i="14118" txt_f="14189">). Rimonabant increased HDL-cholesterol by 7.1% compared with placebo (</offsets><italic><offsets xml_i="20384" xml_f="20385" txt_i="14189" txt_f="14190">P</offsets></italic><offsets xml_i="20394" xml_f="20479" txt_i="14190" txt_f="14272"> &lt; .0001). Rimonabant reduced triglyceride levels by 10.6% compared with placebo (</offsets><italic><offsets xml_i="20487" xml_f="20488" txt_i="14272" txt_f="14273">P</offsets></italic><offsets xml_i="20497" xml_f="20685" txt_i="14273" txt_f="14461"> = .0047).  The mean waist circumference decreased  from baseline by 5.93 ± 0.33 cm in the rimonabant 20-mg group compared with 3.2 ± 0.33 cm in the placebo group (−2.8 cm versus placebo; </offsets><italic><offsets xml_i="20693" xml_f="20694" txt_i="14461" txt_f="14462">P</offsets></italic><offsets xml_i="20703" xml_f="20717" txt_i="14462" txt_f="14473"> &lt; .0001) (</offsets><xref ref-type="fig" rid="fig4"><offsets xml_i="20749" xml_f="20760" txt_i="14473" txt_f="14484">Figure 4(c)</offsets></xref><offsets xml_i="20767" xml_f="21001" txt_i="14484" txt_f="14718">). In this nondiabetic population, minimal, nonsignificant changes were observed in fasting glucose and fasting insulin in both  groups at 9 months, with, however, a favorable trend for rimonabant 20 mg, especially in fasting insulin.</offsets></p></sec><sec sec-type="subsection" id="sec3.4"><title><offsets xml_i="21057" xml_f="21075" txt_i="14720" txt_f="14738">3.4. Safety Events</offsets></title><p><offsets xml_i="21086" xml_f="21188" txt_i="14739" txt_f="14841">The incidence of treatment-emergent adverse events (TEAEs) was higher in the rimonabant group (66.0%, </offsets><italic><offsets xml_i="21196" xml_f="21197" txt_i="14841" txt_f="14842">n</offsets></italic><offsets xml_i="21206" xml_f="21254" txt_i="14842" txt_f="14890"> = 210) compared with the placebo group (56.8%, </offsets><italic><offsets xml_i="21262" xml_f="21263" txt_i="14890" txt_f="14891">n</offsets></italic><offsets xml_i="21272" xml_f="21281" txt_i="14891" txt_f="14900"> = 184) (</offsets><xref ref-type="table" rid="tab4"><offsets xml_i="21315" xml_f="21322" txt_i="14900" txt_f="14907">Table 4</offsets></xref><offsets xml_i="21329" xml_f="21451" txt_i="14907" txt_f="15029">). The percentage of patients who permanently discontinued due to TEAEs was low and comparable between the placebo (2.8%, </offsets><italic><offsets xml_i="21459" xml_f="21460" txt_i="15029" txt_f="15030">n</offsets></italic><offsets xml_i="21469" xml_f="21497" txt_i="15030" txt_f="15058"> = 9) and rimonabant (3.1%, </offsets><italic><offsets xml_i="21505" xml_f="21506" txt_i="15058" txt_f="15059">n</offsets></italic><offsets xml_i="21515" xml_f="21946" txt_i="15059" txt_f="15490"> = 10) groups. Serious TEAEs were more frequently reported in the placebo group compared with the rimonabant 20 mg group (4.6% versus 3.1%) with no deaths reported during the study period. The most frequent adverse events (≥0.5%) leading to treatment discontinuation were dizziness in the rimonabant 20 mg group (0.9% versus 0.6% in placebo) and headache (0.6% versus 0.0% in rimonabant 20 mg) in the placebo group  (data on file).</offsets></p><p><offsets xml_i="21953" xml_f="21978" txt_i="15491" txt_f="15516">In the rimonabant group (</offsets><xref ref-type="table" rid="tab4"><offsets xml_i="22012" xml_f="22019" txt_i="15516" txt_f="15523">Table 4</offsets></xref><offsets xml_i="22026" xml_f="22355" txt_i="15523" txt_f="15852">), the common adverse events reported with a ≥2% incidence (≥1% over placebo patients) were upper respiratory tract infections (10.7% versus 9.0%), nausea (11.6% versus 4.0%), diarrhea (7.5% versus 4.3%), dyspepsia (3.1% versus 0.6%), vomiting (2.8% versus 0.9%), dizziness (10.7% versus 9.6%), and depression (4.1% versus 0.9%).</offsets></p></sec></sec><sec sec-type="section" id="sec4"><title><offsets xml_i="22412" xml_f="22425" txt_i="15855" txt_f="15868">4. Discussion</offsets></title><p><offsets xml_i="22436" xml_f="22865" txt_i="15869" txt_f="16298">This 9-month RIO-Asia study showed that rimonabant 20 mg is effective in reducing body weight in obese Asians. The 9-month treatment period with rimonabant was considered to be sufficient to compare the efficacy and safety of rimonabant with placebo, based on the results from previous RIO studies. A significantly greater reduction in weight was observed in the rimonabant 20-mg group compared with the placebo group (−2.99 kg, </offsets><italic><offsets xml_i="22873" xml_f="22874" txt_i="16298" txt_f="16299">P</offsets></italic><offsets xml_i="22883" xml_f="22897" txt_i="16299" txt_f="16310"> &lt; .0001). </offsets></p><p><offsets xml_i="22904" xml_f="23227" txt_i="16311" txt_f="16634">The percentage of patients who achieved at least 5% (53.0%) and 10% (20%) reduction of their baseline body weight with rimonabant treatment at 9 months was more than twice (21.5%) and four times (5.7%) compared with placebo. In obesity, a 5% decrease in body weight is associated with an improved cardiometabolic profile  [</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="23259" xml_f="23261" txt_i="16634" txt_f="16636">11</offsets></xref><offsets xml_i="23268" xml_f="23270" txt_i="16636" txt_f="16638">].</offsets></p><p><offsets xml_i="23277" xml_f="23480" txt_i="16639" txt_f="16842">The reduction in waist circumference followed the same pattern as body weight reduction. Obesity guidelines for Asia-Pacific have recommended a waist circumference of  ≥90 cm in men and ≥80 cm in women [</offsets><xref ref-type="bibr" rid="B25"><offsets xml_i="23512" xml_f="23514" txt_i="16842" txt_f="16844">25</offsets></xref><offsets xml_i="23521" xml_f="23863" txt_i="16844" txt_f="17186">]. Since rimonabant decreased the mean waist circumference by 2.8 cm, reduction in abdominal obesity would also lower the risk of developing related metabolic disorders. International Day for the Evaluation of Obesity (IDEA) study established a graded relationship between waist circumference, diabetes mellitus, and cardiovascular disease  [</offsets><xref ref-type="bibr" rid="B27"><offsets xml_i="23895" xml_f="23897" txt_i="17186" txt_f="17188">27</offsets></xref><offsets xml_i="23904" xml_f="23906" txt_i="17188" txt_f="17190">].</offsets></p><p><offsets xml_i="23913" xml_f="24114" txt_i="17191" txt_f="17392">Significant improvements in HDL-cholesterol and triglycerides, associated with the reduction in weight and waist circumference, were seen in the rimonabant 20 mg group compared with the placebo group (</offsets><italic><offsets xml_i="24122" xml_f="24123" txt_i="17392" txt_f="17393">P</offsets></italic><offsets xml_i="24132" xml_f="24145" txt_i="17393" txt_f="17403"> &lt; .001,  </offsets><italic><offsets xml_i="24153" xml_f="24154" txt_i="17403" txt_f="17404">P</offsets></italic><offsets xml_i="24163" xml_f="24473" txt_i="17404" txt_f="17714"> = .0047, resp.). Hence, the results of this study indicate that treatment with rimonabant would have favourable effects on body weight and cardiometabolic risk profile in obese Asians who are known to have a greater incidence of obesity-related metabolic disorders at a lower BMI as compared with Caucasians [</offsets><xref ref-type="bibr" rid="B22"><offsets xml_i="24505" xml_f="24507" txt_i="17714" txt_f="17716">22</offsets></xref><offsets xml_i="24514" xml_f="24516" txt_i="17716" txt_f="17718">].</offsets></p><p><offsets xml_i="24523" xml_f="24852" txt_i="17719" txt_f="18048">The results in this RIO-Asia study are consistent with those in the 4 previous double-blind, placebo-controlled RIO studies (RIO-Lipids, RIO-Europe, RIO-Diabetes, and RIO-North America) conducted in more than 6000 patients, where rimonabant 20 mg had shown a significant reduction in body weight at 1 year compared with placebo (</offsets><italic><offsets xml_i="24860" xml_f="24861" txt_i="18048" txt_f="18049">P</offsets></italic><offsets xml_i="24870" xml_f="25453" txt_i="18049" txt_f="18629"> &lt; .001 versus placebo). In Rio-Asia, the mean decrease in weight induced by rimonabant, compared with placebo, in the ITT population was 2.99 kg which was lower than RIO-North America (5.2 kg), RIO-Europe (5.3 kg), and RIO-Lipids (6.0 kg) on day 252 (data on file). The lower mean loss in body weight in the RIO-Asia study could be attributed to the lower baseline weights in Asian study population (81.48 kg) as compared with the Caucasian populations in the other studies (93.2–102.7 kg), but the percentage change in the weight loss was comparable among the different studies.</offsets></p><p><offsets xml_i="25460" xml_f="25554" txt_i="18630" txt_f="18724">In this study, similar results for weight loss was observed across both BMI strata (25–27 kg/m</offsets><sup><offsets xml_i="25559" xml_f="25560" txt_i="18724" txt_f="18725">2</offsets></sup><offsets xml_i="25566" xml_f="25582" txt_i="18725" txt_f="18738"> and &gt;27 kg/m</offsets><sup><offsets xml_i="25587" xml_f="25588" txt_i="18738" txt_f="18739">2</offsets></sup><offsets xml_i="25594" xml_f="25671" txt_i="18739" txt_f="18816">). Rimonabant decreased weight by 5.61% in the group with a BMI 25 to 27 kg/m</offsets><sup><offsets xml_i="25676" xml_f="25677" txt_i="18816" txt_f="18817">2</offsets></sup><offsets xml_i="25683" xml_f="25733" txt_i="18817" txt_f="18864"> and by 6.11% in the group with a BMI &gt; 27 kg/m</offsets><sup><offsets xml_i="25738" xml_f="25739" txt_i="18864" txt_f="18865">2</offsets></sup><offsets xml_i="25745" xml_f="25900" txt_i="18865" txt_f="19020">, which can lower the risk of developing related metabolic disorders. Metabolic disorders are initiated at a lower BMI in Asians compared with Caucasians [</offsets><xref ref-type="bibr" rid="B22"><offsets xml_i="25932" xml_f="25934" txt_i="19020" txt_f="19022">22</offsets></xref><offsets xml_i="25941" xml_f="26075" txt_i="19022" txt_f="19156">]. The BMI cut-off points for overweight and obesity are different in the Asian population as compared with the Caucasian population [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="26106" xml_f="26107" txt_i="19156" txt_f="19157">1</offsets></xref><offsets xml_i="26114" xml_f="26116" txt_i="19157" txt_f="19159">, </offsets><xref ref-type="bibr" rid="B22"><offsets xml_i="26148" xml_f="26150" txt_i="19159" txt_f="19161">22</offsets></xref><offsets xml_i="26157" xml_f="26159" txt_i="19161" txt_f="19163">, </offsets><xref ref-type="bibr" rid="B25"><offsets xml_i="26191" xml_f="26193" txt_i="19163" txt_f="19165">25</offsets></xref><offsets xml_i="26200" xml_f="26358" txt_i="19165" txt_f="19323">]. In the IDEA study, which involved 177, 345 patients in 63 countries, one half to two thirds of the study population were overweight or obese (BMI ≥ 25 kg/m</offsets><sup><offsets xml_i="26363" xml_f="26364" txt_i="19323" txt_f="19324">2</offsets></sup><offsets xml_i="26370" xml_f="26510" txt_i="19324" txt_f="19461">). The frequency of diabetes mellitus and coronary vascular disease increased with waist circumference in all categories of BMI (&lt;25 kg/m</offsets><sup><offsets xml_i="26515" xml_f="26516" txt_i="19461" txt_f="19462">2</offsets></sup><offsets xml_i="26522" xml_f="26534" txt_i="19462" txt_f="19474">, 25–30 kg/m</offsets><sup><offsets xml_i="26539" xml_f="26540" txt_i="19474" txt_f="19475">2</offsets></sup><offsets xml_i="26546" xml_f="26563" txt_i="19475" txt_f="19489">, and &gt;30 kg/m</offsets><sup><offsets xml_i="26568" xml_f="26569" txt_i="19489" txt_f="19490">2</offsets></sup><offsets xml_i="26575" xml_f="26578" txt_i="19490" txt_f="19493">) [</offsets><xref ref-type="bibr" rid="B27"><offsets xml_i="26610" xml_f="26612" txt_i="19493" txt_f="19495">27</offsets></xref><offsets xml_i="26619" xml_f="26754" txt_i="19495" txt_f="19630">]. In adult Korean population, the incidence of diabetes, hypertension, and dyslipidemia was 2 times more at a BMI of 23.0 to 24.0 kg/m</offsets><sup><offsets xml_i="26759" xml_f="26760" txt_i="19630" txt_f="19631">2</offsets></sup><offsets xml_i="26766" xml_f="26805" txt_i="19631" txt_f="19670"> and 3 times more at a BMI of 26.0 kg/m</offsets><sup><offsets xml_i="26810" xml_f="26811" txt_i="19670" txt_f="19671">2</offsets></sup><offsets xml_i="26817" xml_f="26819" txt_i="19671" txt_f="19673"> [</offsets><xref ref-type="bibr" rid="B28"><offsets xml_i="26851" xml_f="26853" txt_i="19673" txt_f="19675">28</offsets></xref><offsets xml_i="26860" xml_f="27049" txt_i="19675" txt_f="19864">]. In Chinese population, the inclination to accumulate truncal body fat is associated with metabolic complications, which occur at a lower BMI than in European/North American populations [</offsets><xref ref-type="bibr" rid="B21"><offsets xml_i="27081" xml_f="27083" txt_i="19864" txt_f="19866">21</offsets></xref><offsets xml_i="27090" xml_f="27092" txt_i="19866" txt_f="19868">, </offsets><xref ref-type="bibr" rid="B29"><offsets xml_i="27124" xml_f="27126" txt_i="19868" txt_f="19870">29</offsets></xref><offsets xml_i="27133" xml_f="27135" txt_i="19870" txt_f="19872">].</offsets></p><p><offsets xml_i="27142" xml_f="27767" txt_i="19873" txt_f="20498">Safety evaluation in this study found that rimonabant 20 mg was generally well tolerated in the Asian study population. The most common adverse events reported with an incidence ≥2% in the rimonabant group were upper respiratory tract infection, nausea, diarrhea, dyspepsia, vomiting, dizziness, depression, anxiety, insomnia, hyperhidrosis, palpitations, and fatigue. In addition, a lower number of patients discontinued treatment due to adverse events and this number was comparable between the 2 treatment groups (3.1% versus 2.8%, in rimonabant and placebo group, resp.). Among neuropsychiatric events, depression (4.1%, </offsets><italic><offsets xml_i="27775" xml_f="27776" txt_i="20498" txt_f="20499">n</offsets></italic><offsets xml_i="27785" xml_f="27811" txt_i="20499" txt_f="20525"> = 13) and anxiety (3.8%, </offsets><italic><offsets xml_i="27819" xml_f="27820" txt_i="20525" txt_f="20526">n</offsets></italic><offsets xml_i="27829" xml_f="27899" txt_i="20526" txt_f="20596"> = 12) were higher in the rimonabant 20 mg compared to placebo (0.9%, </offsets><italic><offsets xml_i="27907" xml_f="27908" txt_i="20596" txt_f="20597">n</offsets></italic><offsets xml_i="27917" xml_f="27932" txt_i="20597" txt_f="20612"> = 3 and 1.5%, </offsets><italic><offsets xml_i="27940" xml_f="27941" txt_i="20612" txt_f="20613">n</offsets></italic><offsets xml_i="27950" xml_f="28238" txt_i="20613" txt_f="20901"> = 5). A meta-analysis of randomized trials involving rimonabant 20 mg/day has proposed that rimonabant increases the risk of psychiatric adverse events including depression and anxiety. Patients were 2.5 and 3.0 times more likely to discontinue rimonabant due to depression and anxiety [</offsets><xref ref-type="bibr" rid="B30"><offsets xml_i="28270" xml_f="28272" txt_i="20901" txt_f="20903">30</offsets></xref><offsets xml_i="28279" xml_f="28508" txt_i="20903" txt_f="21132">]. An overview of the RIO programme with rimonabant was published recently, which reviewed and summarized the overall efficacy and side effects of RIO trials including RIO-Europe, RIO-North America, RIO-Lipids, and RIO-Diabetes [</offsets><xref ref-type="bibr" rid="B31"><offsets xml_i="28540" xml_f="28542" txt_i="21132" txt_f="21134">31</offsets></xref><offsets xml_i="28549" xml_f="29385" txt_i="21134" txt_f="21970">]. The vast majority of the test populations are western ethnics. The overall TEAE-induced drug discontinuation rate was higher in the rimonabant than the placebo groups either without (13.6% versus 7.7%, resp.) or with diabetes (15.0% versus 5.5%, resp.). The reported AE of depression was increased in the rimonabant group, either in all obese cohort (3.9% versus 1.7%, resp.) or in diabetes programme (2.5% versus 1.4%, resp.). The TEAE-induced drug discontinuation rate in RIO-Asia seems to be much lower than that of other RIO trials. Although the RIO-Asia has relatively a smaller sample size and shorter duration than other RIO trials, the reported AE of depression rate is still significantly increased in the rimonabant group in Asian population. Hence, monitoring of rimonabant-induced psychiatric adverse events is essential.</offsets></p><p><offsets xml_i="29392" xml_f="29826" txt_i="21971" txt_f="22405">The endocannabinoid system (ECS), encompassing endocannabinoids including  anandamide and 2-arachidonoylglycerol (2-AG), two cannabinoid receptors, type 1 (CB1) and type 2 (CB2), and enzymes responsible for endogenous ligand synthesis (phospholipase D) and degradation (fatty acid amide hydrolase (FAAH)), is a complex physiological system involved in metabolic homeostasis such as modulating energy fluxes and nutrients  regulation [</offsets><xref ref-type="bibr" rid="B32"><offsets xml_i="29858" xml_f="29860" txt_i="22405" txt_f="22407">32</offsets></xref><offsets xml_i="29867" xml_f="30691" txt_i="22407" txt_f="23231">]. Recently, substantial clinical evidence revealed that CB1 antagonists might result in risks of severe psychiatric problems, including depression, anxiety, and stress disorders, especially in those with underlying or susceptible psychological problems. These findings have made rimonabant (SR14176A), the first CB1 inverse agonist approved and launched in Europe in 2006, withdrawn from the market in 2008, and thereof, several CB1 target-related candidates including taranabant (MK-0364) and otenabant (CP-945598) were suspended at the late clinical development stage (phase III). In the meanwhile, increased evidence indicates that CB1 receptors present in the peripheral tissue, including fat and liver, might regulate food intake and energy balance as effectively as those present in the central nervous system (CNS) [</offsets><xref ref-type="bibr" rid="B33"><offsets xml_i="30723" xml_f="30725" txt_i="23231" txt_f="23233">33</offsets></xref><offsets xml_i="30732" xml_f="31232" txt_i="23233" txt_f="23733">]. This provides a rationale for development of peripherally preferred or restricted CB1 antagonists which possess minimized CNS adverse reactions and preserve antiobesity effects. Recently, this strategy of developing CB1 antagonists without penetrating blood-brain barrier (BBB) was found to meet with a certain degree of success. Sufficient weight-reduction efficacy and less CNS toxic profile have been observed with romonabant-mimicking analogues acting exclusively on peripheral CB1 receptors [</offsets><xref ref-type="bibr" rid="B34"><offsets xml_i="31264" xml_f="31266" txt_i="23733" txt_f="23735">34</offsets></xref><offsets xml_i="31273" xml_f="31334" txt_i="23735" txt_f="23796">]. However, these compounds have been tested only in animals.</offsets></p></sec><sec sec-type="section" id="sec5"><title><offsets xml_i="31385" xml_f="31398" txt_i="23798" txt_f="23811">5. Conclusion</offsets></title><p><xref ref-type="bibr" rid="B35"><offsets xml_i="31441" xml_f="31443" txt_i="23812" txt_f="23814">35</offsets></xref><offsets xml_i="31450" xml_f="31871" txt_i="23814" txt_f="24235">]. Perceptively, to avoid untoward CNS side effects in drug discovery for the intervention of the endocannabinoids system, an appealing strategy of development of peripherally restricted and highly CB1/CB2 selective antagonists may be desired. Some compounds of this kind have been shown to have promising results in lowering propensity to pass the blood-brain barrier with preserved weight-reducing effects in DIO mice [</offsets><xref ref-type="bibr" rid="B36"><offsets xml_i="31903" xml_f="31905" txt_i="24235" txt_f="24237">36</offsets></xref><offsets xml_i="31912" xml_f="31914" txt_i="24237" txt_f="24239">, </offsets><xref ref-type="bibr" rid="B37"><offsets xml_i="31946" xml_f="31948" txt_i="24239" txt_f="24241">37</offsets></xref><offsets xml_i="31955" xml_f="32136" txt_i="24241" txt_f="24422">]. Another peripheral-acting CB1 neutral antagonist has been shown to have weight-independent effects on improving cardiometabolic risks and fatty liver in mouse models of obesity [</offsets><xref ref-type="bibr" rid="B38"><offsets xml_i="32168" xml_f="32170" txt_i="24422" txt_f="24424">38</offsets></xref><offsets xml_i="32177" xml_f="32277" txt_i="24424" txt_f="24524">].  However, the clinical efficacy and safety of these new antiobesity compounds are yet to be seen.</offsets></p></sec><sec sec-type="section" id="sec6"><title><offsets xml_i="32328" xml_f="32351" txt_i="24526" txt_f="24549"> Conflict of Interests </offsets></title><p><offsets xml_i="32362" xml_f="32408" txt_i="24550" txt_f="24596">The authors declared no conflict of interests.</offsets></p></sec></body><back><ack><title>Acknowledgments</title><p>Dr. L. T. Ho acknowledges the assistance of Drs. C. F. Kwok, H. S. Chen, and S. C. Chiang for the RIO Asia study. This study was partly supported by a research Grant V97-C1-026 to Dr. Ho.</p></ack><ref-list><ref id="B1"><label>1</label><element-citation publication-type="other"><article-title>Global activity on diet, physical activity and health; obesity and overweight</article-title><comment>WHO 2008, <ext-link ext-link-type="uri" xlink:href="http://www.who.int/dietphysicalactivity/publications/facts/obesity/en/">http://www.who.int/dietphysicalactivity/publications/facts/obesity/en/</ext-link></comment></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y</given-names></name></person-group><article-title>Overweight and obesity in China</article-title><source><italic>British Medical Journal</italic></source><year>2006</year><volume>333</volume><issue>7564</issue><fpage>362</fpage><lpage>363</lpage><pub-id pub-id-type="pmid">16916811</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>NF</given-names></name></person-group><article-title>Prevalence of obesity in Taiwan</article-title><source><italic>Obesity Reviews</italic></source><year>2005</year><volume>6</volume><issue>4</issue><fpage>271</fpage><lpage>274</lpage><pub-id pub-id-type="pmid">16246212</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>DM</given-names></name><name><surname>Ahn</surname><given-names>CW</given-names></name><name><surname>Nam</surname><given-names>SY</given-names></name></person-group><article-title>National prevalence of obesity: prevalence of obesity in Korea</article-title><source><italic>Obesity Reviews</italic></source><year>2005</year><volume>6</volume><issue>2</issue><fpage>117</fpage><lpage>121</lpage><pub-id pub-id-type="pmid">15836462</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herling</surname><given-names>AW</given-names></name><name><surname>Kilp</surname><given-names>S</given-names></name><name><surname>Elvert</surname><given-names>R</given-names></name><name><surname>Haschke</surname><given-names>G</given-names></name><name><surname>Kramer</surname><given-names>W</given-names></name></person-group><article-title>Increased energy expenditure contributes more to the body weight-reducing effect of rimonabant than reduced food intake in candy-fed wistar rats</article-title><source><italic>Endocrinology</italic></source><year>2008</year><volume>149</volume><issue>5</issue><fpage>2557</fpage><lpage>2566</lpage><pub-id pub-id-type="pmid">18276749</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sonnenberg</surname><given-names>GE</given-names></name><name><surname>Krakower</surname><given-names>GR</given-names></name><name><surname>Kissebah</surname><given-names>AH</given-names></name></person-group><article-title>A novel pathway to the manifestations of metabolic syndrome</article-title><source><italic>Obesity Research</italic></source><year>2004</year><volume>12</volume><issue>2</issue><fpage>180</fpage><lpage>186</lpage><pub-id pub-id-type="pmid">14981209</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poirier</surname><given-names>P</given-names></name><name><surname>Giles</surname><given-names>TD</given-names></name><name><surname>Bray</surname><given-names>GA</given-names></name><etal></etal></person-group><article-title>Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss</article-title><source><italic>Arteriosclerosis, Thrombosis, and Vascular Biology</italic></source><year>2006</year><volume>26</volume><issue>5</issue><fpage>968</fpage><lpage>976</lpage></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohnishi</surname><given-names>H</given-names></name><name><surname>Saitoh</surname><given-names>S</given-names></name><name><surname>Akasaka</surname><given-names>H</given-names></name><etal></etal></person-group><article-title>Incidence of hypertension in individuals with abdominal obesity in a rural Japanese population: the Tanno and Sobetsu study</article-title><source><italic>Hypertension Research</italic></source><year>2008</year><volume>31</volume><issue>7</issue><fpage>1385</fpage><lpage>1390</lpage><pub-id pub-id-type="pmid">18957809</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vgontzas</surname><given-names>AN</given-names></name><name><surname>Papanicolaou</surname><given-names>DA</given-names></name><name><surname>Bixler</surname><given-names>EO</given-names></name><etal></etal></person-group><article-title>Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia</article-title><source><italic>Journal of Clinical Endocrinology and Metabolism</italic></source><year>2000</year><volume>85</volume><issue>3</issue><fpage>1151</fpage><lpage>1158</lpage><pub-id pub-id-type="pmid">10720054</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>HJ</given-names></name><name><surname>Ji</surname><given-names>EY</given-names></name><name><surname>Eun</surname><given-names>JP</given-names></name><etal></etal></person-group><article-title>Body mass index and cancer risk in Korean men and women</article-title><source><italic>International Journal of Cancer</italic></source><year>2008</year><volume>123</volume><issue>8</issue><fpage>1892</fpage><lpage>1896</lpage></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akbas</surname><given-names>F</given-names></name><name><surname>Gasteyger</surname><given-names>C</given-names></name><name><surname>Sjödin</surname><given-names>A</given-names></name><name><surname>Astrup</surname><given-names>A</given-names></name><name><surname>Larsen</surname><given-names>TM</given-names></name></person-group><article-title>A critical review of the cannabinoid receptor as a drug target for obesity management</article-title><source><italic>Obesity Reviews</italic></source><year>2009</year><volume>10</volume><issue>1</issue><fpage>58</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">18721231</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bronander</surname><given-names>KA</given-names></name><name><surname>Bloch</surname><given-names>MJ</given-names></name></person-group><article-title>Potential role of the endocannabinoid receptor antagonist rimonabant in the management of cardiometabolic risk: a narrative review of available data</article-title><source><italic>Vascular Health and Risk Management</italic></source><year>2007</year><volume>3</volume><issue>2</issue><fpage>181</fpage><lpage>190</lpage><pub-id pub-id-type="pmid">17580728</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shire</surname><given-names>D</given-names></name><name><surname>Calandra</surname><given-names>B</given-names></name><name><surname>Delpech</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Structural features of the central cannabinoid CB1 receptor involved in the binding of the specific CB1 antagonist SR 141716A</article-title><source><italic>Journal of Biological Chemistry</italic></source><year>1996</year><volume>271</volume><issue>12</issue><fpage>6941</fpage><lpage>6946</lpage><pub-id pub-id-type="pmid">8636122</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bifulco</surname><given-names>M</given-names></name><name><surname>Grimaldi</surname><given-names>C</given-names></name><name><surname>Gazzerro</surname><given-names>P</given-names></name><name><surname>Pisanti</surname><given-names>S</given-names></name><name><surname>Santoro</surname><given-names>A</given-names></name></person-group><article-title>Rimonabant: just an antiobesity drug? Current evidence on its pleiotropic effects</article-title><source><italic>Molecular Pharmacology</italic></source><year>2007</year><volume>71</volume><issue>6</issue><fpage>1445</fpage><lpage>1456</lpage><pub-id pub-id-type="pmid">17327463</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quarta</surname><given-names>C</given-names></name><name><surname>Bellocchio</surname><given-names>L</given-names></name><name><surname>Mancini</surname><given-names>G</given-names></name><etal></etal></person-group><article-title>CB(1) signaling in forebrain and sympathetic neurons is a key determinant of endocannabinoid actions on energy balance</article-title><source><italic>Cell Metabolism</italic></source><year>2010</year><volume>11</volume><issue>4</issue><fpage>273</fpage><lpage>285</lpage><pub-id pub-id-type="pmid">20374960</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gary-Bobo</surname><given-names>M</given-names></name><name><surname>Elachouri</surname><given-names>G</given-names></name><name><surname>Gallas</surname><given-names>JF</given-names></name><etal></etal></person-group><article-title>Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese zucker fa/fa rats</article-title><source><italic>Hepatology</italic></source><year>2007</year><volume>46</volume><issue>1</issue><fpage>122</fpage><lpage>129</lpage><pub-id pub-id-type="pmid">17526015</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Marzo</surname><given-names>V</given-names></name></person-group><article-title>The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation</article-title><source><italic>Pharmacological Research</italic></source><year>2009</year><volume>60</volume><issue>2</issue><fpage>77</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">19559360</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Gaal</surname><given-names>LF</given-names></name><name><surname>Rissanen</surname><given-names>AM</given-names></name><name><surname>Scheen</surname><given-names>AJ</given-names></name><name><surname>Ziegler</surname><given-names>O</given-names></name><name><surname>Rössner</surname><given-names>S</given-names></name></person-group><article-title>Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study</article-title><source><italic>Lancet</italic></source><year>2005</year><volume>365</volume><issue>9468</issue><fpage>1389</fpage><lpage>1397</lpage><pub-id pub-id-type="pmid">15836887</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pi-Sunyer</surname><given-names>FX</given-names></name><name><surname>Aronne</surname><given-names>LJ</given-names></name><name><surname>Heshmati</surname><given-names>HM</given-names></name><name><surname>Devin</surname><given-names>J</given-names></name><name><surname>Rosenstock</surname><given-names>J</given-names></name></person-group><article-title>Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients—RIO-North America: a randomized controlled trial</article-title><source><italic>Journal of the American Medical Association</italic></source><year>2006</year><volume>295</volume><issue>7</issue><fpage>761</fpage><lpage>775</lpage><pub-id pub-id-type="pmid">16478899</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Després</surname><given-names>JP</given-names></name><name><surname>Golay</surname><given-names>A</given-names></name><name><surname>Sjöström</surname><given-names>L</given-names></name></person-group><article-title>Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia</article-title><source><italic>New England Journal of Medicine</italic></source><year>2005</year><volume>353</volume><issue>20</issue><fpage>2121</fpage><lpage>2134</lpage><pub-id pub-id-type="pmid">16291982</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levine</surname><given-names>JA</given-names></name></person-group><article-title>Obesity in China: causes and solutions</article-title><source><italic>Chinese Medical Journal</italic></source><year>2008</year><volume>121</volume><issue>11</issue><fpage>1043</fpage><lpage>1050</lpage><pub-id pub-id-type="pmid">18706257</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>Y</given-names></name><name><surname>Youn</surname><given-names>KS</given-names></name><name><surname>Choi</surname><given-names>H</given-names></name></person-group><article-title>BMI and metabolic disorders in South Korean adults: 1998 Korea National Health and Nutrition Survey</article-title><source><italic>Obesity Research</italic></source><year>2004</year><volume>12</volume><issue>3</issue><fpage>445</fpage><lpage>453</lpage><pub-id pub-id-type="pmid">15044661</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barba</surname><given-names>C</given-names></name><name><surname>Cavalli-Sforza</surname><given-names>T</given-names></name><name><surname>Cutter</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies</article-title><source><italic>Lancet</italic></source><year>2004</year><volume>363</volume><issue>9403</issue><fpage>157</fpage><lpage>163</lpage><pub-id pub-id-type="pmid">14726171</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>C-J</given-names></name><name><surname>Wu</surname><given-names>C-H</given-names></name><name><surname>Chang</surname><given-names>C-S</given-names></name><etal></etal></person-group><article-title>Low body mass index but high percent body fat in Taiwanese subjects: implications of obesity cutoffs</article-title><source><italic>International Journal of Obesity</italic></source><year>2003</year><volume>27</volume><issue>2</issue><fpage>253</fpage><lpage>259</lpage><pub-id pub-id-type="pmid">12587007</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="other"><collab>World Health Organization Western Pacific Region, International Association for the Study of Obesity and International Obesity Task Force</collab><article-title>The Asia-Pacific perspective: redefining obesity and its treatment</article-title><comment>Australia: Health Communications Australia Pty Limited, 2000</comment></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Kooy</surname><given-names>K</given-names></name><name><surname>Seidell</surname><given-names>JC</given-names></name></person-group><article-title>Techniques for the measurement of visceral fat: a practical guide</article-title><source><italic>International Journal of Obesity</italic></source><year>1993</year><volume>17</volume><issue>4</issue><fpage>187</fpage><lpage>196</lpage><pub-id pub-id-type="pmid">8387967</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balkau</surname><given-names>B</given-names></name><name><surname>Deanfield</surname><given-names>JE</given-names></name><name><surname>Després</surname><given-names>JP</given-names></name><etal></etal></person-group><article-title>International day for the evaluation of abdominal obesity (IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168 000 primary care patients in 63 countries</article-title><source><italic>Circulation</italic></source><year>2007</year><volume>116</volume><issue>17</issue><fpage>1942</fpage><lpage>1951</lpage><pub-id pub-id-type="pmid">17965405</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallagher</surname><given-names>D</given-names></name></person-group><article-title>Overweight and obesity BMI cut-offs and their relation to metabolic disorders in Koreans/Asians</article-title><source><italic>Obesity Research</italic></source><year>2004</year><volume>12</volume><issue>3</issue><fpage>440</fpage><lpage>441</lpage><pub-id pub-id-type="pmid">15044659</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>WH</given-names></name><name><surname>Flegal</surname><given-names>KM</given-names></name><name><surname>Chang</surname><given-names>HY</given-names></name><name><surname>Yeh</surname><given-names>WT</given-names></name><name><surname>Yeh</surname><given-names>CJ</given-names></name><name><surname>Lee</surname><given-names>WC</given-names></name></person-group><article-title>Body mass index and obesity-related metabolic disorders in Taiwanese and US whites and blacks: implications for definitions of overweight and obesity for Asians</article-title><source><italic>American Journal of Clinical Nutrition</italic></source><year>2004</year><volume>79</volume><issue>1</issue><fpage>31</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">14684394</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christensen</surname><given-names>R</given-names></name><name><surname>Kristensen</surname><given-names>PK</given-names></name><name><surname>Bartels</surname><given-names>EM</given-names></name><name><surname>Bliddal</surname><given-names>H</given-names></name><name><surname>Astrup</surname><given-names>A</given-names></name></person-group><article-title>Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials</article-title><source><italic>Lancet</italic></source><year>2007</year><volume>370</volume><issue>9600</issue><fpage>1706</fpage><lpage>1713</lpage><pub-id pub-id-type="pmid">18022033</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheen</surname><given-names>AJ</given-names></name></person-group><article-title>CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant</article-title><source><italic>Journal of Neuroendocrinology</italic></source><year>2008</year><volume>20</volume><issue>supplement 1</issue><fpage>139</fpage><lpage>146</lpage><pub-id pub-id-type="pmid">18426513</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janero</surname><given-names>DR</given-names></name><name><surname>Makriyannis</surname><given-names>A</given-names></name></person-group><article-title>Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis</article-title><source><italic>Expert Opinion on Emerging Drugs</italic></source><year>2009</year><volume>14</volume><issue>1</issue><fpage>43</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">19249987</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Storr</surname><given-names>MA</given-names></name><name><surname>Sharkey</surname><given-names>KA</given-names></name></person-group><article-title>The endocannabinoid system and gut-brain signalling</article-title><source><italic>Current Opinion in Pharmacology</italic></source><year>2007</year><volume>7</volume><issue>6</issue><fpage>575</fpage><lpage>582</lpage><pub-id pub-id-type="pmid">17904903</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>LoVerme</surname><given-names>J</given-names></name><name><surname>Duranti</surname><given-names>A</given-names></name><name><surname>Tontini</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Synthesis and characterization of a peripherally restricted CB cannabinoid antagonist, URB447, that reduces feeding and body-weight gain in mice</article-title><source><italic>Bioorganic and Medicinal Chemistry Letters</italic></source><year>2009</year><volume>19</volume><issue>3</issue><fpage>639</fpage><lpage>643</lpage><pub-id pub-id-type="pmid">19128970</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Posner</surname><given-names>K</given-names></name><name><surname>Oquendo</surname><given-names>MA</given-names></name><name><surname>Gould</surname><given-names>M</given-names></name><name><surname>Stanley</surname><given-names>B</given-names></name><name><surname>Davies</surname><given-names>M</given-names></name></person-group><article-title>Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA’s pediatric suicidal risk analysis of antidepressants</article-title><source><italic>American Journal of Psychiatry</italic></source><year>2007</year><volume>164</volume><issue>7</issue><fpage>1035</fpage><lpage>1043</lpage><pub-id pub-id-type="pmid">17606655</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>CH</given-names></name><name><surname>Hung</surname><given-names>MS</given-names></name><name><surname>Song</surname><given-names>JS</given-names></name><etal></etal></person-group><article-title>Discovery of 2-[5-(4-chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-ethyl-1H- pyrazol-3-yl]-1,5,5-trimethyl-1,5-dihydro-imidazol-4-thione (BPR-890) via an active metabolite. A novel, potent and selective cannabinoid-1 receptor inverse agonist with high antiobesity efficacy in DIO mice</article-title><source><italic>Journal of Medicinal Chemistry</italic></source><year>2009</year><volume>52</volume><issue>14</issue><fpage>4496</fpage><lpage>4510</lpage><pub-id pub-id-type="pmid">19530697</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Receveur</surname><given-names>JM</given-names></name><name><surname>Murray</surname><given-names>A</given-names></name><name><surname>Linget</surname><given-names>JM</given-names></name><etal></etal></person-group><article-title>Conversion of 4-cyanomethyl-pyrazole-3-carboxamides into CB1 antagonists with lowered propensity to pass the blood-brain-barrier</article-title><source><italic>Bioorganic and Medicinal Chemistry Letters</italic></source><year>2010</year><volume>20</volume><issue>2</issue><fpage>453</fpage><lpage>457</lpage><pub-id pub-id-type="pmid">20015647</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tam</surname><given-names>J</given-names></name><name><surname>Vemuri</surname><given-names>VK</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity</article-title><source><italic>Journal of Clinical Investigation</italic></source><year>2010</year><volume>120</volume><issue>8</issue><fpage>2953</fpage><lpage>2966</lpage><pub-id pub-id-type="pmid">20664173</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="fig1" position="float"><label>Figure 1</label><caption><p>Flow of patients in RIO Asia study.</p></caption><graphic xlink:href="JOBES2011-957268.001"></graphic></fig><fig id="fig2" position="float"><label>Figure 2</label><caption><p>Effect of rimonabant on (a) weight at each visit and at 9 months (b) 5% and 10% weight responders.</p></caption><graphic xlink:href="JOBES2011-957268.002"></graphic></fig><fig id="fig3" position="float"><label>Figure 3</label><caption><p>Changes in weight in intent to treat population stratified by BMI (last observation carried forward).</p></caption><graphic xlink:href="JOBES2011-957268.003"></graphic></fig><fig id="fig4" position="float"><label>Figure 4</label><caption><p>Effect of rimonabant on HDL-cholesterol, triglycerides, and waist circumference at each visit and at 9 months.</p></caption><graphic xlink:href="JOBES2011-957268.004"></graphic></fig><table-wrap id="tab1" position="float"><label>Table 1</label><caption><p>Demographic characteristics and comorbidities.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"></th><th align="left" rowspan="1" colspan="1">Placebo (<italic>N</italic> = 324)</th><th align="left" rowspan="1" colspan="1">Rimonabant  20 mg  (<italic>N</italic> = 318)</th><th align="left" rowspan="1" colspan="1">Overall  (<italic>N</italic> = 642)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><italic>Age (years) </italic></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">Overall, mean (SD)</td><td align="left" rowspan="1" colspan="1">35.3 (10.5)</td><td align="left" rowspan="1" colspan="1">36.7 (10.8)</td><td align="left" rowspan="1" colspan="1">36.0 (10.7)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Age group</italic>, <italic>n</italic> (%)</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">&lt;18</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1 (0.3%)</td><td align="left" rowspan="1" colspan="1">1 (0.2%)</td></tr><tr><td align="left" rowspan="1" colspan="1">[18–49]</td><td align="left" rowspan="1" colspan="1">294 (90.7%)</td><td align="left" rowspan="1" colspan="1">273 (85.8%)</td><td align="left" rowspan="1" colspan="1">567 (88.3%)</td></tr><tr><td align="left" rowspan="1" colspan="1">[50–64]</td><td align="left" rowspan="1" colspan="1">27 (8.3%)</td><td align="left" rowspan="1" colspan="1">41 (12.9%)</td><td align="left" rowspan="1" colspan="1">68 (10.6%)</td></tr><tr><td align="left" rowspan="1" colspan="1">≥65</td><td align="left" rowspan="1" colspan="1">3 (0.9%)</td><td align="left" rowspan="1" colspan="1">3 (0.9%)</td><td align="left" rowspan="1" colspan="1">6 (0.9%)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Gender</italic>, <italic>n</italic> (%)</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">103 (31.8%)</td><td align="left" rowspan="1" colspan="1">99 (31.1%)</td><td align="left" rowspan="1" colspan="1">202 (31.5%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Female</td><td align="left" rowspan="1" colspan="1">221 (68.2%)</td><td align="left" rowspan="1" colspan="1">219 (68.9%)</td><td align="left" rowspan="1" colspan="1">440 (68.5%)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Country</italic>, <italic>n</italic> (%)</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">China</td><td align="left" rowspan="1" colspan="1">121 (37.3%)</td><td align="left" rowspan="1" colspan="1">119 (37.4%)</td><td align="left" rowspan="1" colspan="1">240 (37.4%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Republic of Korea</td><td align="left" rowspan="1" colspan="1">101 (31.2%)</td><td align="left" rowspan="1" colspan="1">99 (31.1%)</td><td align="left" rowspan="1" colspan="1">200 (31.2%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Taiwan</td><td align="left" rowspan="1" colspan="1">102 (31.5%)</td><td align="left" rowspan="1" colspan="1">100 (31.4%)</td><td align="left" rowspan="1" colspan="1">202 (31.5%)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic></italic>, <italic>n</italic> (%)</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">Hypertension</td><td align="left" rowspan="1" colspan="1"> 42 (13.0%)</td><td align="left" rowspan="1" colspan="1">     51 (16.0%)</td><td align="left" rowspan="1" colspan="1">93  (14.5%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Dyslipidemia</td><td align="left" rowspan="1" colspan="1">73 (22.5%)</td><td align="left" rowspan="1" colspan="1">73 (23.0%)</td><td align="left" rowspan="1" colspan="1"> 146 (22.7%)</td></tr></tbody></table></table-wrap><table-wrap id="tab2" position="float"><label>Table 2</label><caption><p>Baseline characteristics: randomized and expose patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"></th><th align="center" rowspan="1" colspan="1">Placebo (<italic>N</italic> = 324)</th><th align="center" rowspan="1" colspan="1">Rimonabant 20 mg (<italic>N</italic> = 318)</th><th align="center" rowspan="1" colspan="1">Overall   (<italic>N</italic> = 642)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><italic>Weight (kg) </italic></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">Mean (SD)</td><td align="center" rowspan="1" colspan="1">82.00 (16.40)</td><td align="center" rowspan="1" colspan="1">80.95 (14.90)</td><td align="center" rowspan="1" colspan="1">81.48 (15.67)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Waist (cm) </italic></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">Male, <italic>n</italic> (%)</td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">&gt;90 cm</td><td align="center" rowspan="1" colspan="1">97 (94.2%)</td><td align="center" rowspan="1" colspan="1">92 (92.9%)</td><td align="center" rowspan="1" colspan="1">189 (93.6%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Female, <italic>n</italic> (%)</td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">&gt;80 cm</td><td align="center" rowspan="1" colspan="1">209 (94.6%)</td><td align="center" rowspan="1" colspan="1">211 (96.3%)</td><td align="center" rowspan="1" colspan="1">420 (95.5%)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>BMI (kg/m<sup>2</sup>) </italic></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">Mean (SD)</td><td align="center" rowspan="1" colspan="1">30.45 (4.41)</td><td align="center" rowspan="1" colspan="1">30.07 (4.04)</td><td align="center" rowspan="1" colspan="1">30.26 (4.23)</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI group, <italic>n</italic> (%)</td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">&lt;25</td><td align="center" rowspan="1" colspan="1">1 (0.3%)</td><td align="center" rowspan="1" colspan="1">     1 (0.3%)</td><td align="center" rowspan="1" colspan="1">2 (0.3%)</td></tr><tr><td align="left" rowspan="1" colspan="1">[25–27]</td><td align="center" rowspan="1" colspan="1">69 (21.3%)</td><td align="center" rowspan="1" colspan="1">     70 (22.0%)</td><td align="center" rowspan="1" colspan="1">139 (21.7%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&gt;27</td><td align="center" rowspan="1" colspan="1">254 (78.4%)</td><td align="center" rowspan="1" colspan="1">247 (77.7%)</td><td align="center" rowspan="1" colspan="1">501 (78.0%)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>HDL-cholesterol (mmol/L)</italic></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">Mean (SD)</td><td align="center" rowspan="1" colspan="1">1.35 (0.29)</td><td align="center" rowspan="1" colspan="1">1.35 (0.29)</td><td align="center" rowspan="1" colspan="1">1.35 (0.29)</td></tr><tr><td align="left" rowspan="1" colspan="1">HDL-cholesterol group, <italic>n</italic> (%)</td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">M: &lt;1.036, F: &lt;1.295</td><td align="center" rowspan="1" colspan="1">100 (30.9%)</td><td align="center" rowspan="1" colspan="1">119 (37.4%)</td><td align="center" rowspan="1" colspan="1">219 (34.1%)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Triglycerides (mmol/L) </italic></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">Mean (SD)</td><td align="center" rowspan="1" colspan="1">1.57 (1.01)</td><td align="center" rowspan="1" colspan="1">     1.59 (0.98)</td><td align="center" rowspan="1" colspan="1">1.58 (0.99)</td></tr><tr><td align="left" rowspan="1" colspan="1">Triglycerides group, <italic>n</italic> (%)</td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">≥1.69</td><td align="center" rowspan="1" colspan="1">99 (30.7%)</td><td align="center" rowspan="1" colspan="1">101 (31.9%)</td><td align="center" rowspan="1" colspan="1">200 (31.3%)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>LDL-cholesterol (mmol/L) </italic></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">Mean (SD)</td><td align="center" rowspan="1" colspan="1">3.08 (0.72)</td><td align="center" rowspan="1" colspan="1">3.01 (0.72)</td><td align="center" rowspan="1" colspan="1">3.04 (0.72)</td></tr><tr><td align="left" rowspan="1" colspan="1">LDL-cholesterol group, <italic>n</italic> (%)</td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">≥3.36</td><td align="center" rowspan="1" colspan="1">113 (34.9%)</td><td align="center" rowspan="1" colspan="1">97 (30.5%)</td><td align="center" rowspan="1" colspan="1">210 (32.7%)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Total/HDL-cholesterol </italic></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">Mean (SD)</td><td align="center" rowspan="1" colspan="1">      3.70 (0.96)</td><td align="center" rowspan="1" colspan="1">     3.65 (0.97)</td><td align="center" rowspan="1" colspan="1">3.67 (0.97)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Fasting glucose (mmol/L) </italic></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">Mean (SD)</td><td align="center" rowspan="1" colspan="1">   5.07 (0.48)</td><td align="center" rowspan="1" colspan="1">    5.17 (0.56)</td><td align="center" rowspan="1" colspan="1">5.12 (0.52)</td></tr><tr><td align="left" rowspan="1" colspan="1">Fasting glucose group, <italic>n</italic> (%)</td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">IFG: ≥5.55 and &lt;6.99</td><td align="center" rowspan="1" colspan="1">    43 (13.4%)</td><td align="center" rowspan="1" colspan="1">    68 (21.5%)</td><td align="center" rowspan="1" colspan="1">111 (17.4%)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Fasting insulin (pmol/L)</italic></td><td align="center" rowspan="1" colspan="1">      92.04 (57.41)</td><td align="center" rowspan="1" colspan="1">98.30 (158.08)</td><td align="center" rowspan="1" colspan="1">   95.17 (118.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean (SD)</td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>HbA1c</italic> (%)</td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">Mean (SD)</td><td align="center" rowspan="1" colspan="1">  5.56 (0.39)</td><td align="center" rowspan="1" colspan="1">  5.61 (0.41)</td><td align="center" rowspan="1" colspan="1">5.59 (0.40)</td></tr></tbody></table><table-wrap-foot><fn><p>BMI: body mass index. HDL: high-density lipoprotein.  IFG: impaired fasting glucose. LDL: low-density lipoprotein. HbA1c: glycosylated hemoglobin.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab3" position="float"><label>Table 3</label><caption><p>Change in weight (last observation carried forward) by BMI stratum in intent-to-treat population.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"></th><th align="center" colspan="2" rowspan="1">BMI: 25 to 27 kg/m<sup>2</sup></th><th align="center" colspan="2" rowspan="1">BMI: &gt;27 kg/m<sup>2</sup></th></tr><tr><th align="left" rowspan="1" colspan="1">Weight (kg)</th><th align="center" rowspan="1" colspan="1">Placebo     (<italic>N</italic> = 74)</th><th align="center" rowspan="1" colspan="1">Rimonabant  20 mg (<italic>N</italic> = 71)</th><th align="center" rowspan="1" colspan="1">Placebo               (<italic>N</italic> = 251)</th><th align="center" rowspan="1" colspan="1">Rimonabant 20 mg (<italic>N</italic> = 247) </th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><italic>Baseline </italic></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">Mean (SD)</td><td align="center" rowspan="1" colspan="1">67.42 (6.21)</td><td align="center" rowspan="1" colspan="1">69.28 (7.45)</td><td align="center" rowspan="1" colspan="1">86.19 (16.22)</td><td align="center" rowspan="1" colspan="1">84.23 (14.81)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Month 9 (LOCF) </italic></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">Mean (SD)</td><td align="center" rowspan="1" colspan="1">66.06 (6.93)</td><td align="center" rowspan="1" colspan="1">65.47 (8.51)</td><td align="center" rowspan="1" colspan="1">84.20 (16.50)</td><td align="center" rowspan="1" colspan="1">79.14 (15.33)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Change from baseline</italic></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">Mean (SD)</td><td align="center" rowspan="1" colspan="1">−1.37 (2.95)</td><td align="center" rowspan="1" colspan="1">−3.81 (3.59)</td><td align="center" rowspan="1" colspan="1">−1.99 (4.55)</td><td align="center" rowspan="1" colspan="1">−5.09 (5.37)</td></tr><tr><td align="left" rowspan="1" colspan="1">LS Mean (SEM)</td><td align="center" rowspan="1" colspan="1">−1.35 (0.384)</td><td align="center" rowspan="1" colspan="1">−3.84 (0.387)</td><td align="center" rowspan="1" colspan="1">−2.02 (0.315)</td><td align="center" rowspan="1" colspan="1">−5.18 (0.316)</td></tr><tr><td align="left" rowspan="1" colspan="1">LS Mean Difference (SEM)</td><td align="center" rowspan="1" colspan="1">—</td><td align="center" rowspan="1" colspan="1">−2.49 (0.548)</td><td align="center" rowspan="1" colspan="1">—</td><td align="center" rowspan="1" colspan="1">−3.16 (0.446)</td></tr><tr><td align="left" rowspan="1" colspan="1">95%CI</td><td align="center" rowspan="1" colspan="1">—</td><td align="center" rowspan="1" colspan="1">(−3.570 to −1.403)</td><td align="center" rowspan="1" colspan="1">—</td><td align="center" rowspan="1" colspan="1">(−4.034 to −2.283)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>P</italic> value</td><td align="center" rowspan="1" colspan="1">—</td><td align="center" rowspan="1" colspan="1">&lt;.0001</td><td align="center" rowspan="1" colspan="1">—</td><td align="center" rowspan="1" colspan="1">&lt;.0001</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Percent change from baseline </italic></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">Mean (SD)</td><td align="center" rowspan="1" colspan="1">−2.05 (4.58)</td><td align="center" rowspan="1" colspan="1">−5.61 (5.33)</td><td align="center" rowspan="1" colspan="1">−2.31 (4.94)</td><td align="center" rowspan="1" colspan="1">−6.11 (6.22)</td></tr></tbody></table><table-wrap-foot><fn><p>BMI: body mass index. CI: confidence interval. LS: least square. LOCF: last observation carried forward.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab4" position="float"><label>Table 4</label><caption><p>Most common adverse events (≥2% in  rimonabant-treated patients and ≥1% in placebo).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"></th><th align="center" rowspan="1" colspan="1">Placebo (<italic>N</italic> = 324)</th><th align="center" rowspan="1" colspan="1">Rimonabant  (20 mg) (<italic>N</italic> = 318)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Patients with any TEAE</td><td align="center" rowspan="1" colspan="1">184 (56.8%)</td><td align="center" rowspan="1" colspan="1">210 (66.0%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Patients with any serious TEAE</td><td align="center" rowspan="1" colspan="1">  15 (4.6%)</td><td align="center" rowspan="1" colspan="1">10 (3.1%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Patients with any TEAE leading to death</td><td align="center" rowspan="1" colspan="1">  0</td><td align="center" rowspan="1" colspan="1"> 0</td></tr><tr><td align="left" rowspan="1" colspan="1">Patients permanently discontinued                 due to TEAE</td><td align="center" rowspan="1" colspan="1">               9 (2.8%)</td><td align="center" rowspan="1" colspan="1">                10 (3.1%)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Most common adverse events</italic></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Gastrointestinal disorders</italic></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">Nausea</td><td align="center" rowspan="1" colspan="1">                13 (4.0%)</td><td align="center" rowspan="1" colspan="1">                37 (11.6%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Diarrhea</td><td align="center" rowspan="1" colspan="1">                14 (4.3%)</td><td align="center" rowspan="1" colspan="1">                24 (7.5%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Dyspepsia</td><td align="center" rowspan="1" colspan="1">                2 (0.6%)</td><td align="center" rowspan="1" colspan="1">                10 (3.1%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Vomiting</td><td align="center" rowspan="1" colspan="1">3 (0.9%)</td><td align="center" rowspan="1" colspan="1">9 (2.8%)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Nervous system disorders</italic></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">Dizziness</td><td align="center" rowspan="1" colspan="1">                 31 (9.6%)</td><td align="center" rowspan="1" colspan="1">                 34 (10.7%)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Psychiatric disorders     </italic></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">Insomnia</td><td align="center" rowspan="1" colspan="1">                11 (3.4%)</td><td align="center" rowspan="1" colspan="1">                14 (4.4%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Depression</td><td align="center" rowspan="1" colspan="1">                3 (0.9%)</td><td align="center" rowspan="1" colspan="1">                13 (4.1%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Anxiety</td><td align="center" rowspan="1" colspan="1">5 (1.5%)</td><td align="center" rowspan="1" colspan="1">12 (3.8%)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Skin and subcutaneous tissue disorders</italic></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">Hyperhidrosis</td><td align="center" rowspan="1" colspan="1">                 3 (0.9%)</td><td align="center" rowspan="1" colspan="1">                  7 (2.2%)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Cardiac disorders     </italic></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">Palpitations</td><td align="center" rowspan="1" colspan="1">                3 (0.9%)</td><td align="center" rowspan="1" colspan="1">                  15 (4.7%)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>General disorders and administration site  conditions</italic></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">Fatigue</td><td align="center" rowspan="1" colspan="1">               3 (0.9%)</td><td align="center" rowspan="1" colspan="1">                  8 (2.5%)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Infections and infestations </italic></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">URTI</td><td align="center" rowspan="1" colspan="1">29 (9.0%)</td><td align="center" rowspan="1" colspan="1">34 (10.7%)</td></tr></tbody></table><table-wrap-foot><fn><p>TEAE:  treatment-emergent adverse event; URTI: upper respiratory tract infection. </p></fn><fn><p>Note: TEAEs included all adverse events with an onset date during treatment exposure and up to 75 days following the last study drug intake.</p></fn></table-wrap-foot></table-wrap></floats-group></article>